Taysha Gene Therapies, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Dallas, TX
TSHA chart
What traders are saying about $TSHA
Latest postsTaysha Gene Therapies, Inc. news
- Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
BioSpace ·
- Taysha Gene Therapies (TSHA) Slips 1.12% to $3.96 as Shares Drift Toward Lower End of Trading Range - Algorithmic Stock Picks
https://www.siam.in/ ·
- Taysha Gene Therapies, Inc. Estimates – NASDAQ:TSHA
TradingView ·
- Taysha Gene Therapies Stock Price Forecast. Should You Buy TSHA?
StockInvest.us ·
- Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Yahoo Finance ·
- Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Yahoo Finance ·
- Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Yahoo Finance ·
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Yahoo Finance ·
- These 3 Risky Stocks Could Be Sitting on 100% Upside
marketbeat.com ·
- Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
fool.com ·
- Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
Yahoo Finance ·
Taysha Gene Therapies, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M |
| Diluted EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 |
| Total assets (year end) | $343.3M | $160.4M | $172.7M | $126.3M |
| Cash and equivalents (year end) | $319.8M | $139.0M | $143.9M | $87.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Taysha Gene Therapies, Inc.
- Ticker
- TSHA (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Dallas, TX
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1806310
Frequently asked questions
What exchange is Taysha Gene Therapies, Inc. listed on?
Taysha Gene Therapies, Inc. trades on the Nasdaq under the ticker symbol TSHA.
What industry is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc.'s business address on file with the SEC is in Dallas, TX.
When does Taysha Gene Therapies, Inc.'s fiscal year end?
Taysha Gene Therapies, Inc.'s fiscal year ends on December 31.
How much revenue did Taysha Gene Therapies, Inc. report?
Taysha Gene Therapies, Inc. reported $9.8M in revenue for calendar year 2025, according to its SEC filings.